Published in Cancer Weekly, November 6th, 2001
"Matrix decided to pursue centralized approval in Europe when the EMEA confirmed that IntraDose qualified for this process," said Michael D....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.